Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Sarcoma 6Recurrence 3Osteosarcoma 3Rhabdomyosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia 2Breast Neoplasms 2Vomiting 1Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma, Synovial 1Sarcoma, Myeloid 1Sarcoma, Ewing 1Rhabdoid Tumor 1Neurofibrosarcoma 1Neoplasm Metastasis 1Nausea 1Myeloproliferative Disorders 1Malignant mesenchymal tumor 1Lymphoma, Large B-Cell, Diffuse 1Liposarcoma 1Leukemia, Biphenotypic, Acute 1Leiomyosarcoma 1Hypersensitivity 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Heart Failure 1Fibrosarcoma 1

Interventions

Gemcitabine 15Doxorubicin 8Docetaxel 8Radiotherapy 7Trabectedin 6Nivolumab 5pazopanib 4liposomal doxorubicin 3Sunitinib 3Dacarbazine 3pembrolizumab 2eribulin 2durvalumab 2avelumab 2Specimen Handling 2Radiation Dose Hypofractionation 2Letrozole 2Ifosfamide 2Bevacizumab 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1temsirolimus 1sotigalimab 1selinexor 1sargramostim 1rucaparib 1ribociclib 1regorafenib 1pegfilgrastim 1olaratumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leiomyosarcoma × Dexrazoxane × Clear all
NCT02584309 2023-11-07

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Washington University School of Medicine

Phase 2 Completed
73 enrolled 11 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡